Cargando…

A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer

Translational research in medicine, defined as the transfer of knowledge and discovery from the basic sciences to the clinic, is typically achieved through interactions between members across scientific disciplines to overcome the traditional silos within the community. Thus, translational medicine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramisetty, Sravani, Kulkarni, Prakash, Bhattacharya, Supriyo, Nam, Arin, Singhal, Sharad S., Guo, Linlin, Mirzapoiazova, Tamara, Mambetsariev, Bolot, Mittan, Sandeep, Malhotra, Jyoti, Pisick, Evan, Subbiah, Shanmuga, Rajurkar, Swapnil, Massarelli, Erminia, Salgia, Ravi, Mohanty, Atish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861808/ https://www.ncbi.nlm.nih.gov/pubmed/36675528 http://dx.doi.org/10.3390/jcm12020599

Ejemplares similares

Addressing Drug Resistance in Cancer: A Team Medicine Approach
por: Kulkarni, Prakash, et al.
Publicado: (2022)

Recent Advancement in Breast Cancer Research: Insights from Model Organisms—Mouse Models to Zebrafish
por: Singhal, Sharad S., et al.
Publicado: (2023)

Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors
por: Guo, Linlin, et al.
Publicado: (2023)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer
por: Kulkarni, Prakash, et al.
Publicado: (2023)

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients
por: Poroyko, Valeriy, et al.
Publicado: (2018)

Biomarkers in immunotherapy: literature review and future directions
por: Pharaon, Rebecca, et al.
Publicado: (2020)

HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression
por: Mirzapoiazova, Tamara, et al.
Publicado: (2015)

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer
por: Mirzapoiazova, Tamara, et al.
Publicado: (2021)

A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer
por: Mohanty, Atish, et al.
Publicado: (2020)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
por: Rajurkar, Swapnil, et al.
Publicado: (2020)

Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy
por: Nam, Arin, et al.
Publicado: (2021)

A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer
por: Mohanty, Atish, et al.
Publicado: (2020)

The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer
por: Lennon, Frances E., et al.
Publicado: (2014)

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
por: Mohanty, Atish, et al.
Publicado: (2023)

Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research
por: Subbiah, Shanmuga, et al.
Publicado: (2020)

Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines
por: Mirzapoiazova, Tamara, et al.
Publicado: (2020)

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016)

Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression
por: Reyes, Amanda, et al.
Publicado: (2022)

Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
por: Reyes, Amanda, et al.
Publicado: (2023)

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
por: Sattler, Martin, et al.
Publicado: (2023)

Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2022)

The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations
por: Melas, Marilena, et al.
Publicado: (2020)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Integration of artificial intelligence in lung cancer: Rise of the machine
por: Ladbury, Colton, et al.
Publicado: (2023)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2018)

Extracellular Vesicles from Caveolin-Enriched Microdomains Regulate Hyaluronan-Mediated Sustained Vascular Integrity
por: Mirzapoiazova, Tamara, et al.
Publicado: (2015)

Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
por: Reckamp, Karen L, et al.
Publicado: (2020)

Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas
por: Srivastava, Saumya, et al.
Publicado: (2020)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
por: Roosan, Moom R., et al.
Publicado: (2021)

Illuminating Intrinsically Disordered Proteins with Integrative Structural Biology
por: Evans, Rachel, et al.
Publicado: (2023)

Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions
por: Pathak, Ranjan, et al.
Publicado: (2021)

Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma
por: Wang, Jiale, et al.
Publicado: (2018)

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2021)

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology
por: Mambetsariev, Isa, et al.
Publicado: (2019)

GRP78 is a novel receptor initiating a vascular barrier protective response to oxidized phospholipids
por: Birukova, Anna A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dndq0ga0t5rlrkfiq94189d2m3